Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in the 2024 Wells Fargo Healthcare Conference. Jack Khattar, President and CEO, will engage in a fireside chat on September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts.
Investors can arrange meetings with company management through the Wells Fargo conference coordinator. A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 60 days post-conference. This event provides an opportunity for Supernus to showcase its developments in CNS treatments to potential investors and industry professionals.
Supernus Pharmaceuticals (Nasdaq: SUPN), un'azienda biopharmaceutica specializzata nelle malattie del sistema nervoso centrale (CNS), ha annunciato la sua partecipazione alla Conferenza Sanitaria Wells Fargo 2024. Jack Khattar, Presidente e CEO, parteciperà a un incontro informale il 4 settembre 2024, alle 16:30 ET presso l'Encore Boston Harbor Hotel a Everett, Massachusetts.
Gli investitori possono organizzare incontri con il management dell'azienda attraverso il coordinatore della conferenza Wells Fargo. Un audio streaming live della presentazione sarà disponibile sul sito web dell'azienda, con una registrazione archiviatata accessibile per 60 giorni dopo la conferenza. Questo evento offre a Supernus l'opportunità di mostrare i suoi sviluppi nei trattamenti CNS a potenziali investitori e professionisti del settore.
Supernus Pharmaceuticals (Nasdaq: SUPN), una empresa biofarmacéutica especializada en enfermedades del sistema nervioso central (CNS), ha anunciado su participación en la Conferencia de Salud Wells Fargo 2024. Jack Khattar, Presidente y CEO, participará en una charla informal el 4 de septiembre de 2024 a las 4:30 p.m. ET en el Encore Boston Harbor Hotel en Everett, Massachusetts.
Los inversores pueden organizar reuniones con la gestión de la empresa a través del coordinador de la conferencia Wells Fargo. Una transmisión de audio en vivo de la presentación estará disponible en el sitio web de la empresa, con una repetición archivada accesible durante 60 días después de la conferencia. Este evento ofrece a Supernus la oportunidad de mostrar sus avances en tratamientos CNS a inversores potenciales y profesionales de la industria.
Supernus Pharmaceuticals (Nasdaq: SUPN)는 중추신경계(CNS) 질환을 전문으로 하는 생명공학 기업으로, 2024 웰스파고 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Jack Khattar 사장 겸 CEO는 2024년 9월 4일 오후 4:30 ET에 매사추세츠주 에버렛의 Encore Boston Harbor Hotel에서 대화 세션에 참가할 예정입니다.
투자자들은 웰스파고 컨퍼런스 코디네이터를 통해 회사 경영진과의 회의를 아양할 수 있습니다. 해당 발표의 실시간 오디오 웹캐스트는 회사 웹사이트에서 제공되며, 회의 후 60일 동안 아카이브 재생이 가능합니다. 이 행사에서는 Supernus가 CNS 치료의 발전을 잠재적 투자자와 산업 전문가에게 보여줄 수 있는 기회를 제공합니다.
Supernus Pharmaceuticals (Nasdaq: SUPN), une entreprise biopharmaceutique spécialisée dans les maladies du système nerveux central (CNS), a annoncé sa participation à la Conférence sur les soins de santé Wells Fargo 2024. Jack Khattar, Président et CEO, participera à une discussion informelle le 4 septembre 2024 à 16h30 ET à l'Encore Boston Harbor Hotel à Everett, Massachusetts.
Les investisseurs peuvent organiser des réunions avec la direction de l'entreprise par l'intermédiaire du coordinateur de la conférence Wells Fargo. Un webinaire audio en direct de la présentation sera disponible sur le site Web de l'entreprise, avec un replay archivé accessible pendant 60 jours après la conférence. Cet événement offre à Supernus l'opportunité de présenter ses avancées dans les traitements des CNS à de potentiels investisseurs et professionnels du secteur.
Supernus Pharmaceuticals (Nasdaq: SUPN), ein biopharmazeutisches Unternehmen, das auf Zentralnervensystem (CNS) Erkrankungen spezialisiert ist, hat seine Teilnahme an der 2024 Wells Fargo Healthcare Conference bekannt gegeben. Jack Khattar, Präsident und CEO, wird am 4. September 2024 um 16:30 Uhr ET im Encore Boston Harbor Hotel in Everett, Massachusetts, an einem informellen Gespräch teilnehmen.
Investoren können Meetings mit dem Management des Unternehmens über den Konferenzkoordinator von Wells Fargo arrangieren. Ein Live-Audio-Webcast der Präsentation wird auf der Unternehmenswebsite verfügbar sein, mit einem archivierten Replay, das 60 Tage nach der Konferenz zugänglich ist. Diese Veranstaltung bietet Supernus die Gelegenheit, seine Entwicklungen in der CNS-Behandlung potenziellen Investoren und Fachleuten der Branche vorzustellen.
- None.
- None.
ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts.
Investors interested in arranging a meeting with company management during the conference should contact the Wells Fargo conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in PD, cervical dystonia, chronic sialorrhea and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates, including SPN-830; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACT:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
(443) 213-0505
peter.vozzo@westwicke.com
FAQ
When is Supernus Pharmaceuticals (SUPN) participating in the Wells Fargo Healthcare Conference?
Who will represent Supernus Pharmaceuticals (SUPN) at the 2024 Wells Fargo Healthcare Conference?
Where can investors access the webcast of Supernus Pharmaceuticals' (SUPN) presentation at the Wells Fargo conference?
How long will the replay of Supernus Pharmaceuticals' (SUPN) Wells Fargo conference presentation be available?
What is the main focus of Supernus Pharmaceuticals (SUPN)?
